Eli Lilly Considers Investment in US Insulin-Manufacturing Capacity
Company considers investment in insulin cartridge-filling and insulin API manufacturing capacity in the US.
Eli Lilly is considering investing an additional $180 million in the company's insulin-manufacturing operations in Indianapolis, Indiana. The investment is in addition to the company's November 2012 announcement of a $140-million expansion of the company's insulin-manufacturing operations in Indianapolis. Lilly also is proposing several other ancillary investment projects totaling approximately $80 million, including a $40-million product-inspection center.
The latest $180-million proposed investment encompasses two parts. The first part would add a second insulin cartridge-filling line to the company’s previously announced expansion. In November 2012, Lilly announced that it was investing $140 million to expand its Indianapolis facility to support the manufacturing of insulin cartridges with completion targeted for March 2014 and operations beginning in 2015. The new proposed investment would add an additional insulin-cartridge-filling line with target completion by 2016. Filling insulin cartridges is a new technology for Lilly's US manufacturing operations. Lilly sites in the US currently only fill insulin vials, which are used with a traditional syringe or an insulin pump. Cartridges are used in insulin pens.
The second piece of the proposed $180-million investment would increase the company’s insulin-active-ingredient manufacturing capacity. The investment is designed to increase productivity without building a new manufacturing plant or adding to its cost structure. Construction work in the insulin-active-ingredient production area could be completed by December and operational by March 2014, according to the company.
Once operational, approximately 175 full-time technicians, scientists, and engineers would be needed to manage operations in the cartridge-filling and insulin-active-ingredient manufacturing areas. Eli Lilly is working with the city of Indianapolis on its investment proposal.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
